Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 10 other studies
32,490people with arrhythmia, in this paper
The trial randomly assignedassigned by chance
semaglutide
controls
Lowered atrial fibrillation−27%
Lowered complete atrioventricular block−78%
Reduced deaths from CV causes−24%
randomisedthe abstract, start to end
… of atrial fibrillation (AF) (RR 0.73, 95% CI 0.54 to 0.98), complete atrioventricular (AV) block (RR 0.22, 95% CI 0.06 to 0.80), death from CV causes (RR 0.76, 95% CI 0.58 to 0.98), and revascularization (RR 0.68, 95% CI 0.52 to 0.88).
← favours treatmentfavours comparator →
could be chanceAtrial fibrillation (AF)semaglutide vs controls
RR 0.730.54–0.98
Complete atrioventricular (AV) blocksemaglutide vs controls
RR 0.220.06–0.80
Death from CV causessemaglutide vs controls
RR 0.760.58–0.98
Revascularizationsemaglutide vs controls
RR 0.680.52–0.88
GLP-1 receptor agonistsCardiovascular events
GLP-1 receptor agonists × cardiovascular eventshelps?mixed
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 6